サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：In Vitro（体外）大腸癌スクリーニング検査の世界市場
市場調査レポート
商品コード
1198977

In Vitro（体外）大腸癌スクリーニング検査の世界市場

In-Vitro Colorectal Cancer Screening Tests
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
In Vitro（体外）大腸癌スクリーニング検査の世界市場
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のIn Vitro（体外）大腸癌スクリーニング検査の市場規模は、分析期間（2022年～2030年）に3.6％のCAGRで成長する展望で、2022年の8億5,380万米ドルから、2030年には11億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである便潜血検査は、分析期間中に4％の年率で成長し、8億8,150万米ドルに達すると予測されています。

当レポートは、世界のIn Vitro（体外）大腸癌スクリーニング検査市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の展望

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP11160

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global In-Vitro Colorectal Cancer Screening Tests Market to Reach $1.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for In-Vitro Colorectal Cancer Screening Tests estimated at US$853.8 Million in the year 2022, is projected to reach a revised size of US$1.1 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2022-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$881.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biomarker Test segment is readjusted to a revised 1.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $232.6 Million, While China is Forecast to Grow at 6.3% CAGR

The In-Vitro Colorectal Cancer Screening Tests market in the U.S. is estimated at US$232.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$233.4 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.9% and 4.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$149.5 Million by the year 2030.

Select Competitors (Total 44 Featured):

  • Abbott Laboratories, Inc.
  • Alere, Inc.
  • Beckman Coulter, Inc.
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Hemosure, Inc.
  • Novigenix SA
  • Quidel Corporation
  • Sysmex Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • In-Vitro Colorectal Cancer Screening Tests - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Colorectal Cancer: Symptoms, Causes & Risk Factors
    • Screening for Colorectal Cancer
    • Fecal Occult Blood Test
    • Biomarker Test
    • CRC DNA Screening Test
    • Global Market Prospects & Outlook
    • Fecal Occult Blood Tests Dominate Market
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Colorectal Cancer Drives Market Growth
    • Number of New Cancer Cases and Number of Deaths by Type of Cancer in 2020
    • Countries with Highest Rate of Colorectal Cancer: Age-Standardized Cases Per 100000 Population
    • Colorectal Cancer Rates In Men by Country
    • Colorectal Cancer Rates In Women by Country
    • Aging Demographics & Rising Prevalence of Chronic Disorders Enhance Risk of Colorectal Cancer, Necessitating Screening Tests
    • Global Aging Population: 65+ Individuals by Region for 2019 and 2050
    • Life Expectancy at Birth and at 65 Age by Region
    • Launch of Novel Screening Tests for Detection of Inherited Colorectal Cancer to Spur Gene Testing
    • Market to Benefit from Technological Advancements in Cancer Screening Techniques
    • R&D Investments in Development of Advanced DNA Sequencing Methods to Drive Market Opportunities
    • Biomarker Tests for Colorectal Cancer Screening
    • Molecular Markers Gain Prominence for Colorectal Cancer Screening
    • Rising Need for Minimally Invasive Colorectal Cancer Screening Tests Drives Demand for Genetic and DNA Biomarkers
    • At-Home Screening Test for Colorectal Cancer
    • Government Regulations & Guidelines on Cancer Screening: Potential for Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Fecal Occult Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Fecal Occult Blood Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Biomarker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for CRC DNA Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for CRC DNA Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World In-Vitro Colorectal Cancer Screening Tests Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: China 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: China 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: France 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: France Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: France 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: UK 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: UK 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • INDIA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: India 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: India Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: India 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • AFRICA
    • In-Vitro Colorectal Cancer Screening Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by Segment - Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by Segment - Percentage Breakdown of Value Sales for Fecal Occult Blood Test, Biomarker Test and CRC DNA Screening Test for the Years 2014, 2023 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for In-Vitro Colorectal Cancer Screening Tests by End-Use - Hospitals, Clinical Diagnostic Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for In-Vitro Colorectal Cancer Screening Tests by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinical Diagnostic Laboratories and Other End-Uses for the Years 2014, 2023 & 2030

IV. COMPETITION